SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
COVANCE
(NYSE:CVD Last Sale: 85.35 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NYSE: (CVD : $85.35)
$5,456 million Market Cap at September 12, 2013
Employs 6,600.
Drugs SubIndustry up .00% / Health Industry up .00% Today
210 Carnegie Center Research Report Earnings Snapshot - Last 11/03/18
Princeton, NJ 08540 Fact Sheet
Phone: (609) 452-4440 Financial Statements
Fax: (609) 452-4769 Peer Comparison
Annual Reports

Joseph L. Herring, Chmn./Pres./CEO, W. Klitgaard, CFO
Agreed to be acquired by LABORATORY CORP (NYSE:LH) for $6.1 billion in cash and stock November 3, 2014. Holders receive 0.2686 LH and $75.76 cash per CVD. Contract drug development services. Agreed to provide drug development services to Sanofi-aventis for 10 years with estimated payments ranging from $1.2 billion to $2.2 billion September 30, 2010. Sanofi-aventis will utilize Covance's global R&D portfolio of discovery support, toxicology, chemistry, clinical Phase I - IV, central laboratory, and market access services.
Historical Charts    Technical Analysis
No Historical Data available for CVD

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common CVD $85.35 $ 0 $84.47 $85.63 210,123 $46.15 $85.63 63,920
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $5,455,572

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex